- Home
- RCKT vs DFIN Comparison
RCKT vs DFIN Comparison
Compare RCKT & DFIN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RCKT | DFIN |
|---|---|---|
| Founded | 1999 | 1983 |
| Country | United States | United States |
| Employees | 202 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Other Consumer Services |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 401.6M | 991.6M |
| IPO Year | N/A | 2017 |
Fundamental Metrics
Financial Performance| Metric | RCKT | DFIN |
|---|---|---|
| Price | $3.84 | $46.21 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 14 | 2 |
| Target Price | $29.73 | ★ $61.50 |
| AVG Volume (30 Days) | ★ 3.0M | 352.7K |
| Earning Date | 05-04-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 1.27 |
| Revenue | N/A | ★ $963,000,000.00 |
| Revenue This Year | N/A | $4.98 |
| Revenue Next Year | $64.28 | $3.87 |
| P/E Ratio | ★ N/A | $36.39 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $2.53 | $36.11 |
| 52 Week High | $5.45 | $66.25 |
Technical Indicators
Market Signals| Indicator | RCKT | DFIN |
|---|---|---|
| Relative Strength Index (RSI) | 70.84 | 70.44 |
| Support Level | $3.32 | $44.62 |
| Resistance Level | $4.04 | $48.65 |
| Average True Range (ATR) | 0.22 | 1.74 |
| MACD | 0.09 | 0.90 |
| Stochastic Oscillator | 99.16 | 94.24 |
Price Performance
Historical ComparisonAbout RCKT Rocket Pharmaceuticals Inc.
Rocket Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is focused on the development of gene therapies for rare and devastating pediatric diseases. The pipeline products of the company include RP-A501 for Danaon Disease, RP-L102 for Fanconi Anemia, RP-L201 for Leukocyte Adhesion, RP-L301 for Pyruvate Kinase Deficiency, and RP-L401 for Infantile Malignant Osteopetrosis. It has one reportable segment related to R&D and commercial readiness of its gene therapies.
About DFIN Donnelley Financial Solutions Inc.
Donnelley Financial Solutions Inc is a risk and compliance software solutions and related services provider. The company provides regulatory filing and deal solutions via its software-as-a-service, technology-enabled services, and print and distribution solutions to public and private companies, mutual funds, and other regulated investment firms. It operates in four reportable segments: Capital Markets - Software Solutions, Capital Markets - Compliance and Communications Management (its key revenue-generating segment), Investment Companies - Software Solutions, and Investment Companies - Compliance and Communications Management. Its geographical segments are the United States (USA), Europe, Asia, Canada, and Others, of which the USA accounts for the vast majority of its total revenue.